09.04.24 | Vollzeit | Wiesbaden, Mainz, Aschaffenbur | BioNTech SEScientific and ethical standards - writing medical history. We aim to reduce the suffering of people with life-changing therapies by harnessing the potential of the immune system to develop novel therapies against cancer and infectious diseases. While doing so, we are guided by our three company values
Später ansehen08.04.24 | Vollzeit | Unterschleißheim, Landsberg am | CatalYm GmbHOf Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which is markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses
Später ansehen08.04.24 | Vollzeit | München, Königsbrunn, Friedber | CatalYm GmbHOf Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which is markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses
Später ansehen08.04.24 | Vollzeit | München, Königsbrunn, Friedber | CatalYm GmbHOf Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which is markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses
Später ansehen08.04.24 | Vollzeit | Königsbrunn, Friedberg, Münche | CatalYm GmbHOf Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which is markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses
Später ansehen08.04.24 | Vollzeit | Offenbach am Main, Wiesbaden | BioNTech SEScientific and ethical standards - writing medical history. We aim to reduce the suffering of people with life-changing therapies by harnessing the potential of the immune system to develop novel therapies against cancer and infectious diseases. While doing so, we are guided by our three company values
Später ansehen08.04.24 | Vollzeit | Unterschleißheim, Fürstenfeldb | CatalYm GmbHOf Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which is markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses
Später ansehen08.04.24 | Vollzeit | Friedberg, Königsbrunn, Münche | CatalYm GmbHOf Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which is markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses
Später ansehen08.04.24 | Vollzeit | Königsbrunn, Friedberg, Münche | CatalYm GmbHOf Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which is markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses
Später ansehenVerpassen Sie nie wieder einen passenden Job!
Alle Jobs für Immune System Development in Deutschland kostenlos abonnieren.